6L9.F Stock Surges 2400% on XETRA: ViewRay May 2026

ViewRay, Inc. (6L9.F) experienced an extraordinary 2400% surge on the XETRA exchange, reaching €0.025 on May 4, 2026. The medical device manufacturer, which specializes in MRI-guided radiation therapy systems, saw trading volume spike to 3,500 shares—roughly 12.5 times its average daily volume. This dramatic intraday move reflects extreme volatility in a stock that has declined 99.4% over the past year. The company’s market cap stands at approximately €207 million, though investors should note the stock trades at penny levels with significant downside risk. Understanding the fundamentals behind this move is critical for evaluating whether this represents opportunity or danger.

6L9.F Stock Price Action and Trading Dynamics

The 6L9.F stock opened at €0.001 and climbed to a day high of €0.025, marking the explosive 2400% intraday gain. Volume surged dramatically from an average of 279 shares to 3,500 shares, indicating sudden investor interest. The stock’s 52-week range spans from €0.0005 to €4.60, showing extreme volatility and distress. Track 6L9.F on Meyka for real-time updates on this volatile medical device stock.

Price Levels and Technical Context

The current price of €0.025 sits well below the 50-day average of €0.319 and the 200-day average of €2.717. This positioning suggests the stock remains deeply depressed compared to recent trading ranges. The previous close of €0.001 indicates the stock was trading at penny levels before today’s spike. Such extreme moves often occur in distressed or speculative situations where liquidity is thin and small trades can move prices dramatically.

ViewRay’s Business Model and Market Position

ViewRay, Inc. designs and manufactures MRI-guided radiation therapy systems called MRIdian, which address critical challenges in cancer treatment. The company serves university hospitals, community hospitals, private practices, and cancer centers across the United States, France, Taiwan, and the United Kingdom. Founded in 2004 and headquartered in Oakwood, Ohio, ViewRay employs approximately 2,950 people and operates in the Medical Devices industry within the Healthcare sector.

Financial Performance and Profitability

The company faces significant profitability challenges. ViewRay reported a negative EPS of -€0.55 and a negative net profit margin of -105%, meaning it loses money on every euro of revenue. Operating cash flow is negative at -€0.508 per share, and free cash flow is -€0.529 per share. These metrics indicate the company is burning cash and has not yet achieved sustainable profitability despite its innovative technology.

Financial Metrics and Valuation Analysis

The 6L9.F stock trades at a price-to-sales ratio of 2.38, which appears modest but must be contextualized within the company’s losses. The price-to-book ratio is just 0.064, suggesting the stock trades at a significant discount to book value. However, negative earnings make traditional PE ratios meaningless. The company’s debt-to-equity ratio stands at 1.05, indicating moderate leverage, while the current ratio of 2.36 shows adequate short-term liquidity.

Cash Position and Runway

ViewRay maintains €0.752 per share in cash, providing some financial cushion. The company’s working capital totals €131.8 million, which offers runway for operations. However, with negative free cash flow, the company will eventually deplete reserves unless it reaches profitability or secures additional funding. The market cap of €207 million reflects investor skepticism about the company’s path to profitability.

Market Sentiment and Risk Assessment

Trading Activity

The extreme volume spike today—12.5 times average volume—suggests either forced buying, short covering, or speculative interest in a deeply distressed stock. Such moves in penny stocks often lack fundamental justification and can reverse just as quickly. The stock’s year-to-date decline of -99.4% indicates sustained selling pressure from investors losing confidence.

Liquidation Concerns

With negative cash flow and ongoing losses, ViewRay faces potential dilution through equity raises or debt restructuring. The company’s inability to generate positive returns on assets (-39.5%) and equity (-85.2%) raises questions about management’s ability to execute a turnaround. Meyka AI rates 6L9.F with a grade of C+ with a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

The 6L9.F stock surge to €0.025 reflects extreme volatility and thin liquidity rather than fundamental improvement at ViewRay. Despite MRIdian technology addressing real clinical needs, the company faces persistent losses, negative cash flow, and unclear profitability prospects. The 2400% move likely stems from speculative positioning in a distressed medical device company. Investors should exercise extreme caution, as penny-level trading carries substantial risk of total loss, and future capital raises could significantly dilute shareholders.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.